AEGiS-GMHC: TREATMENT BRIEFS: New Drug Tested for Genital Warts

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

TREATMENT BRIEFS: New Drug Tested for Genital Warts

Gay Men's Health Crisis: Treatment Issues, Volume 8 no. 4 - June 1994
David Gold

A topical formulation of HPMPC, an anti-CMV drug being developed by Gilead Sciences, is now being studied as a treatment for anal and genital warts in HIV-infected patients. The trial is ongoing at three sites: the Conant Medical Group, the University of Washington at Seattle, and the Houston Clinical Research Network.

An intravenous (IV) version of HPMPC is now in phase II/III trials for CMV. The drug is believed to work against strains of human papilloma virus (HPV) which are associated with genital warts. HPV has been linked to increased rates of cervical cancer in HIV-positive women and anal cancer in gay and bisexual HIV-positive men. The topical formulation of HPMPC is being administered once a day. It is also being studied in acyclovir-resistant herpes.

According to Dr. Conant's office, early indications from the study for genital warts are "promising." In the first three patients treated (all with anal warts), one patient had a complete clearing, one had "extensive reduction," and one had a self-described 50 percent reduction in warts per day. It should be noted, however, that genital warts clear spontaneously in about 25 percent of cases when a placebo is given. Nevertheless, HPMPC is the first therapy tested against HPV that attacks the virus itself and, according to the company, protects uninfected cells against HPV.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com
9406
GM080418

Copyright © 1994 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .